Connect your agent to akta.pro and build company lists like this across sectors and geos.
Private US AI drug discovery companies, Series A or later, ranked by Q3 2026 primary-subject news volume: funding, products and services, revenue model, news signals and headcount growth for each.
| Company | Funding | Products & Services | Revenue Model | Signals (Q3 2026) | Headcount growth (Q3) |
|---|---|---|---|---|---|
| Chai Discovery ↗ AI Drug Discovery 🇺🇸 San Francisco, USA | Funding $631.0M Last raised $400.0M Jul 2026 · Series C | Generative foundation models (Chai-1, Chai-2, Chai-3) predicting biomolecular structure and designing de novo antibodies and miniproteins, licensed to Eli Lilly and Pfizer. | Licensing Royalties Subscription Recurring Professional Services | 55 in Q3 View signals (29) → | +15% in Q3 39 → 45 employees |
| Enveda Biosciences ↗ Natural Product Drug Discovery 🇺🇸 Boulder, USA | Funding $840.9M Last raised $311.0M Sep 2026 · Series E | AI platform (PRISM) combining mass spectrometry with the world's largest plant-derived molecule library, advancing three clinical-stage small-molecule candidates for inflammation and metabolic disease. | Licensing Royalties Subscription Recurring Transaction Fee | 39 in Q3 View signals (11) → | -3% in Q3 400 → 387 employees |
| Iambic ↗ AI-driven drug discovery platform 🇺🇸 San Diego, USA | Funding $570.3M Last raised $66.0M Sep 2026 · Debt-Funded | AI drug discovery platform (Enchant transformer models, NeuralPLexer structure prediction) with automated wet-lab testing, advancing oncology candidates and licensing the platform to large pharma. | Licensing Royalties | 29 in Q3 View signals (5) → | +8% in Q3 179 → 194 employees |
| Treeline Biosciences ↗ Precision Oncology Drug Discovery 🇺🇸 Watertown, USA | Funding $1.09B Last raised $200.0M Sep 2025 · Series A | Clinical-stage biopharma using a cloud-first computational and machine-learning discovery platform, advancing three Phase 1 precision oncology candidates targeting BCL6, EZH2 and KRAS. | Subscription Recurring Licensing Royalties | 28 in Q3 View signals (14) → | +4% in Q3 167 → 174 employees |
| Aureka Biotechnologies ↗ AI-driven antibody therapeutics discovery 🇺🇸 Laguna Hills, USA | Funding $168.4M Last raised $100.0M Aug 2026 · Series B | AuraIDE platform combining high-throughput synthetic biology, microfluidic screening and a protein language model to design antibodies for pharma partners and an internal pipeline. | Professional Services Licensing Royalties | 23 in Q3 View signals (9) → | +8% in Q3 39 → 42 employees |
| Astromech ↗ Bioinformatics AI Platform 🇺🇸 Austin, USA | Funding $90.5M Last raised $20.0M Aug 2026 · Seed | Large Life Model, a Colossal Biosciences subsidiary's AI system decoding biological regulation and evolutionary logic across multi-species data for therapeutic and trait research. | n/d | 20 in Q3 View signals (13) → | n/d |
| BigHat Biosciences ↗ Antibody Discovery Platform 🇺🇸 San Mateo, USA | Funding $174.3M Last raised $75.0M Sep 2026 · Series C | Milliner platform pairing cell-free synthetic biology with machine learning in a weekly design-build-test-learn loop, partnered with Lilly, J&J, AbbVie, Amgen and Merck. | Professional Services Licensing Royalties | 14 in Q3 View signals (4) → | +1% in Q3 97 → 98 employees |
| Cellular Intelligence ↗ AI Drug Discovery Platform 🇺🇸 Boston, USA | Funding $57.3M Last raised Undisclosed May 2026 · Corporate-Funded | Universal Virtual Cell-Signaling foundation model and a capsule-based data platform rationally designing cell differentiation protocols, advancing a Phase 2-ready Parkinson's cell therapy. | Licensing Royalties | 12 in Q3 View signals (8) → | +3% in Q3 97 → 100 employees |
| Transcripta Bio ↗ AI Drug Discovery Platform 🇺🇸 Palo Alto, USA | Funding $34.4M Last raised $24.0M Jul 2026 · Series A | Drug-Gene Atlas and Conductor AI mapping molecular structure to transcriptome-scale gene expression to discover and repurpose drugs for genetically validated diseases. | Licensing Royalties Data Monetisation | 11 in Q3 View signals (6) → | 0% in Q3 18 → 18 employees |
| Lila Sciences ↗ Scientific AI Platform 🇺🇸 Cambridge, USA | Funding $550.7M Last raised $671.4K Jan 2026 · Grant | Scientific Superintelligence platform pairing the Lila Iris reasoning model with autonomous AI Science Factories, delivered via Catalyst and Creation services across therapeutics and materials. | Managed Services Professional Services | 9 in Q3 View signals (8) → | +11% in Q3 512 → 567 employees |
| ProFound Therapeutics ↗ Therapeutic Discovery Platform 🇺🇸 Cambridge, USA | Funding $95.0M Last raised $20.0M Aug 2026 · Series Unknown | ProFoundry platform combining ribosome profiling with AI/ML to discover novel human proteins and drug targets, licensed to large pharma via multi-year collaborations. | Licensing Royalties | 6 in Q3 View signals (5) → | -2% in Q3 52 → 51 employees |
| Tamarind Bio ↗ Computational Biology Platform 🇺🇸 San Francisco, USA | Funding $13.6M Last raised $13.6M Feb 2026 · Series A | No-code cloud platform hosting 200+ AI/ML and physics-based models for protein structure prediction, antibody and peptide design, serving biotech and top-20 pharma. | Subscription Recurring Managed Services Freemium | 6 in Q3 View signals (1) → | +11% in Q3 19 → 21 employees |
| Arzeda ↗ Protein Design Platform 🇺🇸 Seattle, USA | Funding $212.5M Last raised $21.5M Dec 2025 · Series B | Generative AI protein design platform designing, validating and manufacturing novel enzymes and proteins for Fortune 500 partners in food, home care, materials and pharma. | Others Professional Services Licensing Royalties | 5 in Q3 View signals (3) → | +1% in Q3 78 → 79 employees |
| Inductive Bio ↗ AI-Driven Drug Discovery Software 🇺🇸 San Francisco, USA | Funding $29.3M Last raised $25.0M May 2025 · Series A | Virtual chemistry lab combining ADMET prediction models (Beacon-1), a Compass interface and an AI chemistry assistant (Indy) to help biopharma teams design small molecules. | Subscription Recurring Professional Services Managed Services | 5 in Q3 View signals (4) → | 0% in Q3 42 → 42 employees |
| Profluent Bio ↗ AI Protein Design Platform 🇺🇸 Emeryville, USA | Funding $256.0M Last raised $106.0M Nov 2025 · Series Unknown | Frontier protein language models (ProGen3) authoring novel gene editors, antibodies and enzymes from scratch, delivered to pharma and agriculture partners via licensing and an API. | Licensing Royalties Subscription Recurring Professional Services One Time License | 4 in Q3 View signals (2) → | +6% in Q3 78 → 83 employees |
An AI drug discovery company uses machine learning to find, design or optimise drug candidates faster than traditional lab-driven discovery. The category is also called TechBio or computational drug discovery.
Foundation-model and platform companies such as Chai Discovery, Profluent Bio, Lila Sciences, Tamarind Bio and Inductive Bio build models of molecules and proteins and license them to drug makers.
AI-native drug developers such as Iambic, Enveda Biosciences, Treeline Biosciences, ProFound Therapeutics, Cellular Intelligence and Transcripta Bio apply their platforms to their own pipelines.
Biologics specialists such as Aureka Biotechnologies, BigHat Biosciences, Arzeda and Astromech design antibodies and proteins. The category is defined against traditional pharma discovery and contract research, which rely on wet-lab screening at scale.
Revenue in the table comes mostly from licensing and partnership deals with pharma companies, and none of the 15 companies prices on usage.
Companies are tagged against standard industry codes and against akta.pro's internal taxonomy, so the same set can be rebuilt by code, by segment, or by a combination of both.
NAICSIndustry codes are provided for cross-referencing against public filings and procurement records. akta.pro classification is independent of them, so a company may carry an internal segment without a matching NAICS or SIC registration.